$ATAI
ATAI Life Sciences NV Stock $atai

$atai Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000095017021004541 Filed on November 15, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$230.0K	$266.0K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$25.88M	$20.26M	$71.99M
YoY Change	-64.05%	367.99%
% of Gross Profit
Research & Development	$12.98M	$13.36M	$3.350M
YoY Change	287.52%	336.98%
% of Gross Profit
Depreciation & Amortization	$29.00K	-$7.000K	$14.00K
YoY Change	107.14%	-170.0%
% of Gross Profit
Operating Expenses	$38.86M	$33.63M	$75.34M
YoY Change	-48.42%	355.28%
Operating Profit		-$33.36M
YoY Change		351.68%
Interest Expense	-$3.656M	$6.400M	$378.0K
YoY Change	-1067.2%	-4366.67%
% of Operating Profit
Other Income/Expense, Net	$252.0K	$6.887M	-$3.877M
YoY Change	-106.5%	-149.4%
Pretax Income	-$48.58M	-$26.47M	-$91.24M
YoY Change	-46.76%	24.13%
Income Tax	-$4.421M	$368.0K	$301.0K
% Of Pretax Income
Net Earnings	-$88.88M	-$31.16M	-$86.59M
YoY Change	2.64%	-62.55%
Net Earnings / Revenue	-38642.17%	-11713.53%
Basic Earnings Per Share		-$0.21
Diluted Earnings Per Share	-$592.3K	-$206.2K	-$567.6K
COMMON SHARES
Basic Shares Outstanding	160.3M	151.1M
Diluted Shares Outstanding		151.1M

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$362.3M	$430.3M
YoY Change
Cash & Equivalents	$362.3M	$430.3M	$97.25M
Short-Term Investments
Other Short-Term Assets	$756.0K	$461.0K	$554.0K
YoY Change	36.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$375.1M	$441.9M	$99.55M
YoY Change	276.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$149.0K	$138.0K	$71.00K
YoY Change	109.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$16.13M	$15.09M	$0.00
YoY Change
Other Assets	$7.341M	$1.262M	$339.0K
YoY Change	2065.49%
Total Long-Term Assets	$39.08M	$42.25M	$12.00M
YoY Change	225.7%
TOTAL ASSETS
Total Short-Term Assets	$375.1M	$441.9M	$99.55M
Total Long-Term Assets	$39.08M	$42.25M	$12.00M
Total Assets	$414.2M	$484.1M	$111.5M
YoY Change	271.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.004M	$1.974M	$3.083M
YoY Change	94.75%
Accrued Expenses	$14.83M	$13.08M	$9.215M
YoY Change	60.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$38.00K
YoY Change
Long-Term Debt Due		$38.00K
YoY Change
Total Short-Term Liabilities	$20.94M	$15.32M	$12.30M
YoY Change	70.23%
LONG-TERM LIABILITIES
Long-Term Debt	$743.0K	$800.0K
YoY Change
Other Long-Term Liabilities	$4.097M	$3.285M	$0.00
YoY Change
Total Long-Term Liabilities	$4.097M	$3.285M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.94M	$15.32M	$12.30M
Total Long-Term Liabilities	$4.097M	$3.285M	$0.00
Total Liabilities	$28.21M	$21.35M	$16.18M
YoY Change	74.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$357.8M	-$268.9M	-$190.0M
YoY Change	88.32%
Common Stock	$18.00M	$17.87M	$13.37M
YoY Change	34.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$376.9M	$453.2M	$90.82M
YoY Change
Total Liabilities & Shareholders Equity	$414.2M	$484.1M	$111.5M
YoY Change	271.29%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$88.88M	-$31.16M	-$86.59M
YoY Change	2.64%	-62.55%
Depreciation, Depletion And Amortization	$29.00K	-$7.000K	$14.00K
YoY Change	107.14%	-170.0%
Cash From Operating Activities	-$20.51M	-$28.11M	-$6.214M
YoY Change	230.05%	93.17%
INVESTING ACTIVITIES
Capital Expenditures	-$357.0K	-$318.0K	-$50.00K
YoY Change	614.0%	3433.33%
Acquisitions
YoY Change
Other Investing Activities	-$48.28M	-$296.0K	-$3.816M
YoY Change	1165.09%	-98.79%
Cash From Investing Activities	-$48.63M	-$614.0K	-$3.866M
YoY Change	1157.97%	-97.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.723M	3.877M	81.98M
YoY Change	-97.9%	-87.52%
NET CHANGE
Cash From Operating Activities	-20.51M	-28.11M	-6.214M
Cash From Investing Activities	-48.63M	-614.0K	-3.866M
Cash From Financing Activities	1.723M	3.877M	81.98M
Net Change In Cash	-67.42M	-24.85M	71.90M
YoY Change	-193.77%	215.12%
FREE CASH FLOW
Cash From Operating Activities	-$20.51M	-$28.11M	-$6.214M
Capital Expenditures	-$357.0K	-$318.0K	-$50.00K
Free Cash Flow	-$20.15M	-$27.79M	-$6.164M
YoY Change	226.93%	91.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q3	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss
	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
CY2020Q3	us-gaap	Revenues Revenues
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2020Q3	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability
	atai	Change In Fair Value Of Convertible Promissory Note ChangeInFairValueOfConvertiblePromissoryNote
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue
	atai	Fair Value Of Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity
CY2020Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1
CY2021Q3	atai	Convertible Promissory Notes And Derivative Liability Noncurrent ConvertiblePromissoryNotesAndDerivativeLiabilityNoncurrent
CY2020Q4	us-gaap	Short Term Borrowings ShortTermBorrowings
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts
CY2021Q3	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss
CY2021Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1654
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
CY2020Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
CY2020Q3	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent
CY2021Q3	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal
	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q3	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent
	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent
	atai	Conversion Of Short Term Notes Receivable For Other Investments ConversionOfShortTermNotesReceivableForOtherInvestments
CY2020Q3	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties
CY2021Q3	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1350
	atai	Conversion Of Other Investments Into Equity Method Investments ConversionOfOtherInvestmentsIntoEquityMethodInvestments
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants
CY2021Q3	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent
	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock
	us-gaap	Origination Of Notes Receivable From Related Parties OriginationOfNotesReceivableFromRelatedParties
	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1654
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss
CY2021Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1350
CY2020Q3	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt
	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability
	us-gaap	Revenues Revenues
CY2021Q3	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal
CY2020Q3	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty
	atai	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes
CY2021Q3	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments
CY2021Q3	atai	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent
	dei	Entity Central Index Key EntityCentralIndexKey	0001840904
	atai	Issuance Of Subsidiary Shares In Connection With The Conversion Of Convertible Notes IssuanceOfSubsidiarySharesInConnectionWithTheConversionOfConvertibleNotes
	atai	Loss On Conversion Of Convertible Notes LossOnConversionOfConvertibleNotes
	atai	Fair Value Of Redeemable Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfRedeemableNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity
CY2021Q3	atai	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware
	atai	Proceeds From Sale Of Investment ProceedsFromSaleOfInvestment
	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement
	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40493
	dei	Entity Registrant Name EntityRegistrantName	ATAI Life Sciences N.V.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	P7
	dei	Entity Address Address Line1 EntityAddressAddressLine1	ATAI Life Sciences N.V. c/o Mindspace
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Krausenstraße 9-10
	dei	Entity Address City Or Town EntityAddressCityOrTown	Berlin
	dei	Entity Address Country EntityAddressCountry	DE
	dei	City Area Code CityAreaCode	49 89
	dei	Local Phone Number LocalPhoneNumber	2153 9035
	dei	Security12b Title Security12bTitle	Common shares, par value €0.10 per share
	dei	Trading Symbol TradingSymbol	ATAI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	160297952
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	430308000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97246000
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11551000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2076000
CY2020Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	226000
CY2021Q3	us-gaap	Assets Current AssetsCurrent	441859000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	99548000
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	138000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	71000
CY2020Q4	atai	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	1575000
CY2021Q3	us-gaap	Equity Method Investments EquityMethodInvestments	15086000
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0
CY2021Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	6816000
CY2021Q3	us-gaap	Other Long Term Investments OtherLongTermInvestments	14256000
CY2020Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	8044000
CY2021Q3	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	908000
CY2020Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	911000
CY2021Q3	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	3784000
CY2020Q4	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	1060000
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1262000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	339000
CY2021Q3	us-gaap	Assets Assets	484109000
CY2020Q4	us-gaap	Assets Assets	111548000
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1974000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3083000
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13075000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9215000
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	50000
CY2021Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	180000
CY2021Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	38000
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	15317000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12298000
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1947000
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1705000
CY2021Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	800000
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1199000
CY2021Q3	atai	Convertible Promissory Notes And Derivative Liability Noncurrent Related Party ConvertiblePromissoryNotesAndDerivativeLiabilityNoncurrentRelatedParty	0
CY2020Q4	atai	Convertible Promissory Notes And Derivative Liability Noncurrent Related Party ConvertiblePromissoryNotesAndDerivativeLiabilityNoncurrentRelatedParty	300000
CY2020Q4	atai	Convertible Promissory Notes And Derivative Liability Noncurrent ConvertiblePromissoryNotesAndDerivativeLiabilityNoncurrent	978000
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3285000
CY2021Q3	us-gaap	Liabilities Liabilities	21349000
CY2020Q4	us-gaap	Liabilities Liabilities	16180000
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	173116704
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	159657952
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	159657952
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	114735712
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	114735712
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	17870000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	13372000
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	709475000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	261626000
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5233000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5819000
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-268926000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-189995000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	453186000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	90822000
CY2021Q3	us-gaap	Minority Interest MinorityInterest	9574000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	4546000
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	462760000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	95368000
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	484109000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	111548000
CY2021Q3	us-gaap	Revenues Revenues	266000
	us-gaap	Revenues Revenues	20146000
CY2021Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	13363000
CY2020Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3058000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	34974000
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	8056000
	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	8934000
	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	120000
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20264000
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4328000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	66868000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8749000
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	33627000
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	7386000
	us-gaap	Operating Expenses OperatingExpenses	110776000
	us-gaap	Operating Expenses OperatingExpenses	16925000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-33361000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7386000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-90630000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16925000
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	19000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	80000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	57000
CY2021Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	469000
CY2020Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	86000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-191000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	20000
	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent	718000
CY2020Q3	atai	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	13867000
	atai	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	14000000
CY2020Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-10000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	41000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-23000
CY2021Q3	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	47000
	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	87000
CY2021Q3	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-70000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-5530000
	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	19856000
	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	-513000
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6462000
CY2020Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-159000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	5446000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-191000
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-29000
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-355000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-85000
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6887000
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13942000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2608000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6352000
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-26474000
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-21328000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-88022000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10573000
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	368000
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	432000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
CY2021Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4800000
CY2020Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-61862000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-9440000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-73693000
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-31642000
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-83194000
	us-gaap	Profit Loss ProfitLoss	-80971000
	us-gaap	Profit Loss ProfitLoss	-84270000
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-484000
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2040000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1021000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-31158000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-83195000
	us-gaap	Net Income Loss NetIncomeLoss	-78931000
	us-gaap	Net Income Loss NetIncomeLoss	-83249000
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.92
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.92
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	151130212
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90709312
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	134334685
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90709312
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-31642000
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-83194000
	us-gaap	Profit Loss ProfitLoss	-80971000
	us-gaap	Profit Loss ProfitLoss	-84270000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-9158000
CY2020Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	6329000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11074000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	6216000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-40800000
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-76865000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-92045000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-78054000
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	484000
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76865000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-89983000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-77025000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	35000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-191000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	20000
	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent	718000
	atai	Change In Fair Value Of Convertible Promissory Note ChangeInFairValueOfConvertiblePromissoryNote	14000000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	41000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-23000
	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	87000
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-5530000
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-2062000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1029000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40328000
CY2021Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	4044000
CY2021Q1	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	119993000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	4900000
CY2021Q2	atai	Settlement Of Issuance Of Common Shares Value SettlementOfIssuanceOfCommonSharesValue	140868000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	9000000.0
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	2040000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1021000
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	12000
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-1000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-22000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-8000
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-472000
CY2020Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	95368000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4900000
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	23510000
CY2021Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	885000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	212000
CY2021Q1	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-4026000
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	231581000
CY2021Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	3649000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	37512000
CY2021Q2	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	2110000
CY2021Q2	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-50818000
CY2021Q2	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	484895000
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6424000
CY2021Q3	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12240000
CY2021Q3	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-9158000
CY2021Q3	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-31641000
CY2021Q3	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	462760000
CY2019Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	59638000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	41000
CY2020Q1	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-890000
CY2020Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	15913000
CY2020Q1	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	74702000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	41000
CY2020Q2	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	777000
CY2020Q2	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-16848000
CY2020Q3	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	-15927000
	us-gaap	Profit Loss ProfitLoss	-80971000
	us-gaap	Share Based Compensation ShareBasedCompensation	2221000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	8289000
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	155000
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	43000
CY2020Q2	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	58800000
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2139000
CY2020Q3	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	6329000
CY2020Q3	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-83195000
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-43000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9657000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1093000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1671000
	us-gaap	Profit Loss ProfitLoss	-84270000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	192000
	atai	Loss On Conversion Of Convertible Notes LossOnConversionOfConvertibleNotes	513000
	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	9440000
	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	19856000
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	73693000
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	8934000
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	120000
	us-gaap	Share Based Compensation ShareBasedCompensation	49964000
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	650000
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	47000
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	5362000
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	23659000
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	23164000
	us-gaap	Origination Of Notes Receivable From Related Parties OriginationOfNotesReceivableFromRelatedParties	1232000
	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	2625000
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	273000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	642000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3266000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	859000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	180000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42737000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14552000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	121000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32643000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24405000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	409884000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	12350000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	534000
	atai	Proceeds From Sale Of Investment ProceedsFromSaleOfInvestment	2417000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1587000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	31072000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6067000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	408139000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31072000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	303000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	533000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	333062000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7352000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97246000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30062000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	430308000
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22710000
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	885000
CY2021Q3	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	0
	atai	Fair Value Of Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	392000
	atai	Fair Value Of Redeemable Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfRedeemableNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	2555000
	atai	Issuance Of Subsidiary Shares In Connection With The Conversion Of Convertible Notes IssuanceOfSubsidiarySharesInConnectionWithTheConversionOfConvertibleNotes	3258000
	atai	Conversion Of Short Term Notes Receivable For Other Investments ConversionOfShortTermNotesReceivableForOtherInvestments	9003000
	atai	Conversion Of Other Investments Into Equity Method Investments ConversionOfOtherInvestmentsIntoEquityMethodInvestments	53101000
	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement	120000
	atai	Issuance Of Derivative Instrument Related To Convertible Promissory Notes IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes	646000
	atai	Issuance Of Derivative Instrument Related To Convertible Promissory Notes IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes	203000
	us-gaap	Nature Of Operations NatureOfOperations	<p id="notes" style="text-indent:0.0%;font-size:10.0pt;margin-top:4.2pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ganization and Description of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.093%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ATAI Life Sciences N.V. (“ATAI”) is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. ATAI was founded to address the significant unmet need and lack of innovation in the mental health treatment landscape as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapies.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.093%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since inception, ATAI has either created wholly owned subsidiaries or has made investments in certain controlled entities, including variable interest entities (“VIEs”) for which ATAI is the primary beneficiary under the VIE model (collectively, the “Company”). ATAI is headquartered in Berlin, Germany.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Corporate Reorganization and Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ATAI was incorporated pursuant to the laws of the Netherlands as a Dutch private company with limited liability on September 10, 2020 for the purposes of becoming a holding company for ATAI Life Sciences AG and consummating the corporate reorganization described below. ATAI did not conduct any operations prior to the corporate reorganization other than activities incidental to its formation. ATAI Life Sciences AG was formed as a separate company on February 7, 2018.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In contemplation of the consummation of ATAI’s initial public offering (“IPO”) of common shares, ATAI undertook a corporate reorganization (the “Corporate Reorganization”). The Corporate Reorganization consisted of several steps as described below:</span></p><div style="margin-left:5.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.37986111111111115in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.37986111111111115in;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exchange of ATAI Life Sciences AG Securities for ATAI Life Sciences B.V. Common Shares and Share Split</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: In April 2021, the existing shareholders of ATAI Life Sciences AG each became a party to a separate notarial deed of issue under Dutch law and (i) subscribed for new common shares in ATAI Life Sciences B.V. and (ii) transferred their respective shares in ATAI Life Sciences AG, on a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 to 10 basis</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the “Exchange Ratio”), to ATAI Life Sciences B.V. as a contribution in kind on the common shares in ATAI Life Sciences B.V. As a result of the issuance of common shares in ATAI Life Sciences B.V. to the shareholders of ATAI Life Sciences AG and the contribution and transfer of their respective shares in ATAI Life Sciences AG to ATAI Life Sciences B.V., ATAI Life Sciences AG became a wholly owned subsidiary of ATAI Life Sciences B.V. No shareholder rights or preferences changed as a result of the share for share exchange. In connection with such exchange, the common share in ATAI Life Sciences B.V. held by Apeiron was cancelled. On June 7, 2021, shares of ATAI Life Sciences B.V. were split applying a ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6 to one</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and the nominal value of the shares was reduced to €</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, pursuant to a shareholders’ resolution and amendment to the articles of association.</span></div></div><div style="margin-left:5.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.37986111111111115in;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.37986111111111115in;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Conversion of ATAI Life Sciences B.V. into ATAI Life Sciences N.V</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.: Immediately preceding the Company’s IPO, the legal form of ATAI Life Sciences B.V. was converted from a Dutch private company with limited liability to a Dutch public company, and the articles of association of ATAI Life Sciences N.V., became effective. Following the Corporate Reorganization, ATAI Life Sciences N.V. became the holding company of ATAI Life Sciences AG.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.093%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2945833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Corporate Reorganization, as described above, is considered a continuation of ATAI Life Sciences AG resulting in no change in the carrying values of assets or liabilities. As a result, the financial statements for periods prior to the Corporate Reorganization are the financial statements of ATAI Life Sciences AG as the predecessor to ATAI for accounting and reporting purposes. All share, per-share and related information presented in these condensed consolidated financial statements and corresponding disclosure notes have been retrospectively adjusted, where applicable, to reflect the impact of the share exchange and share split resulting from the Corporate Reorganization. In connection with the Corporate Reorganization, outstanding share awards and option grants of ATAI Life Sciences AG were exchanged for share awards and option grants of ATAI Life Sciences B.V. with identical restrictions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.093%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2945833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 22, 2021, ATAI closed the IPO of its common stock on the Nasdaq Stock Market ("Nasdaq"). As part of the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock, which included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">231.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from the IPO, after deducting underwriters’ discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impact of COVID-19 Pandemic</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.093%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2945833333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic has continued to present global public health and economic challenges during the nine months ended September 30, 2021. Although some research and development timelines have been impacted by delays related to the COVID-19 pandemic, the Company has not experienced material financial impacts on its business and operations as a result. The Company continues to monitor the impact of the COVID-19 pandemic on its employees and business and has undertaken business continuity measures to mitigate potential disruption to its operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The future impact of COVID-19 on the Company’s business and operations, including its research and development programs and related clinical trials, will largely depend on future developments, which are highly uncertain, such as the duration of the pandemic, the spread of the disease and variants thereof, the availability and effectiveness of vaccines and related roll-out efforts, breakthrough infections among the vaccinated, vaccine hesitancy, the implementation of vaccine mandates, travel restrictions, social distancing and related government actions around the world, business closures or business disruptions and the ultimate impact of COVID-19 on financial markets and the global economy. For a discussion of the risks to the Company's business from COVID-19, refer to the section titled “Risk Factors” in the Company’s Prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity and Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred significant losses and negative cash flows from operations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> since its inception. As of September 30, 2021, the Company had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">430.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and its accumulated deficit was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">268.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company has historically financed its operations through the sale of equity securities, sale of convertible notes and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company currently expects that its existing cash and cash equivalents as of September 30, 2021 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the unaudited condensed consolidated financial statements are issued.</span></p>
	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1 to 10 basis
CY2021Q2	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1.6 to one
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	430300000
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-268900000
CY2021Q2	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	484900000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to the fair value of the Company’s short term notes receivable—related party with COMPASS Pathways plc, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">investment in Intelgenx Technologies Corp. (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">“</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IntelGenx</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">”</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">), warrant liability with Neuronasal Inc.,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">convertible promissory notes issued in connection with the 2020 convertible note agreement (the “2020 Convertible Notes”), contingent consideration liability—related parties, derivative liability associated with the Perception convertible promissory notes, in-process research and development assets (“IPRD”), redeemable noncontrolling interests and noncontrolling interests recognized in acquisitions, the valuations of common shares prior to IPO and share-based awards, and accruals for research and development costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:10.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2021Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0
CY2020Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	800000
CY2020Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	4600000
CY2021Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	0
CY2021Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	8000
CY2021Q1	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	100000
	us-gaap	Business Combination Separately Recognized Transactions Net Gains And Losses BusinessCombinationSeparatelyRecognizedTransactionsNetGainsAndLosses	2000
	atai	Purchasesofcommonstock Purchasesofcommonstock	500000
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	500000
CY2021Q3	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.80
CY2020Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.80
CY2021Q3	us-gaap	Minority Interest MinorityInterest	9574000
CY2019Q4	us-gaap	Minority Interest MinorityInterest	887000
CY2020Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0
CY2020Q1	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	0
CY2020Q1	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	0
CY2020Q1	atai	Net Loss Attributable To Redeemable Noncontrolling Interests Common NetLossAttributableToRedeemableNoncontrollingInterestsCommon	-389000
CY2020Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	13000
CY2020Q1	us-gaap	Minority Interest MinorityInterest	511000
CY2020Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0
CY2020Q4	us-gaap	Minority Interest MinorityInterest	4546000
CY2021Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	885000
CY2021Q1	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	870000
CY2021Q1	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	2486000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-184000
CY2021Q1	us-gaap	Minority Interest MinorityInterest	8603000
CY2021Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	3649000
CY2021Q2	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	-2364000
CY2021Q2	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	7000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	150000
CY2021Q2	us-gaap	Minority Interest MinorityInterest	10045000
CY2021Q3	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	-0
CY2021Q3	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-483000
CY2021Q3	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	12000
CY2020Q2	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	0
CY2020Q2	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	0
CY2020Q2	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-491000
CY2020Q2	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-20000
CY2020Q2	us-gaap	Minority Interest MinorityInterest	0
CY2020Q3	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	1000
CY2020Q3	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-1000
CY2020Q3	us-gaap	Minority Interest MinorityInterest	0
CY2021Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2021Q1	atai	Net Loss Attributable To Redeemable Noncontrolling Interests Common NetLossAttributableToRedeemableNoncontrollingInterestsCommon	0
CY2021Q2	atai	Net Loss Attributable To Redeemable Noncontrolling Interests Common NetLossAttributableToRedeemableNoncontrollingInterestsCommon	-2555000
CY2021Q3	atai	Issuance Of Redeemable Noncontrolling Interests IssuanceOfRedeemableNoncontrollingInterests	0
CY2021Q3	atai	Net Loss Attributable To Redeemable Noncontrolling Interests Common NetLossAttributableToRedeemableNoncontrollingInterestsCommon	0
CY2021Q3	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2019Q4	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	142000
CY2020Q1	atai	Net Loss Attributable To Redeemable Noncontrolling Interestspreferred NetLossAttributableToRedeemableNoncontrollingInterestspreferred	-33000
CY2020Q1	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	109000
CY2020Q2	atai	Net Loss Attributable To Redeemable Noncontrolling Interestspreferred NetLossAttributableToRedeemableNoncontrollingInterestspreferred	-109000
CY2020Q2	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2020Q3	atai	Net Loss Attributable To Redeemable Noncontrolling Interestspreferred NetLossAttributableToRedeemableNoncontrollingInterestspreferred	0
CY2020Q3	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2021Q3	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	21100000
CY2021Q3	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	3800000
CY2020Q4	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	8000000.0
CY2020Q4	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	200000
CY2021Q3	us-gaap	Equity Method Investments EquityMethodInvestments	15086000
CY2021Q3	us-gaap	Other Long Term Investments OtherLongTermInvestments	14256000
CY2020Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	8044000
	atai	Equity Method Investment Shares Transaction Date EquityMethodInvestmentSharesTransactionDate	2026-12-31
	us-gaap	Subsidiary Or Equity Method Investee Cumulative Proceeds Received On All Transactions SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions	9600000
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2400000
CY2020Q3	us-gaap	Shares Outstanding SharesOutstanding	7052003
CY2020Q4	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	378100000
CY2021Q3	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	241200000
	us-gaap	Unrealized Gain Loss On Marketable Securities Cost Method Investments And Other Investments UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments	19900000
CY2021Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3000000.0
CY2021Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	9000000.0
	atai	Change In Fair Value Of Short Term Notes Receivable ChangeInFairValueOfShortTermNotesReceivable	700000
CY2021Q3	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	100000
CY2021Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	800000
CY2020Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	200000
CY2021Q2	atai	Fair Value Of Common Stock By Applying Discount For Lack Of Marketability FairValueOfCommonStockByApplyingDiscountForLackOfMarketability	0.137
CY2021Q3	atai	Fair Value Of Common Stock By Applying Discount For Lack Of Marketability FairValueOfCommonStockByApplyingDiscountForLackOfMarketability	0.050
CY2021Q3	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	47000
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	336000
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	10000
CY2020Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	225000
CY2021Q3	atai	Prepaid Research And Development Related Expenses PrepaidResearchAndDevelopmentRelatedExpenses	3070000
CY2020Q4	atai	Prepaid Research And Development Related Expenses PrepaidResearchAndDevelopmentRelatedExpenses	313000
CY2021Q3	atai	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	1105000
CY2020Q4	atai	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	556000
CY2021Q3	us-gaap	Prepaid Taxes PrepaidTaxes	2281000
CY2020Q4	us-gaap	Prepaid Taxes PrepaidTaxes	509000
CY2021Q3	us-gaap	Prepaid Insurance PrepaidInsurance	4634000
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	144000
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	461000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	554000
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11551000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2076000
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3690000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2858000
CY2021Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	5927000
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	997000
CY2021Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1388000
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	347000
CY2021Q3	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	1930000
CY2020Q4	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	1098000
CY2021Q3	atai	Accrued Advisory Fees Current AccruedAdvisoryFeesCurrent	132000
CY2020Q4	atai	Accrued Advisory Fees Current AccruedAdvisoryFeesCurrent	3819000
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	96000
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13075000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9215000
CY2021Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-8000
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-18000
CY2021Q3	us-gaap	Convertible Debt ConvertibleDebt	800000
CY2020Q4	us-gaap	Convertible Debt ConvertibleDebt	1199000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	14135776
	atai	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesExchanged	1152192
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13419360
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	9.69
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	11.71
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	152200000
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4900000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3000
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	368000
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	432000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-31642000
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-83194000
	us-gaap	Profit Loss ProfitLoss	-80971000
	us-gaap	Profit Loss ProfitLoss	-84270000
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-484000
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2040000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1021000
CY2021Q3	atai	Net Income Attributable To Common Stockholders Basic And Diluted NetIncomeAttributableToCommonStockholdersBasicAndDiluted	-31158000
CY2020Q3	atai	Net Income Attributable To Common Stockholders Basic And Diluted NetIncomeAttributableToCommonStockholdersBasicAndDiluted	-83195000
	atai	Net Income Attributable To Common Stockholders Basic And Diluted NetIncomeAttributableToCommonStockholdersBasicAndDiluted	-78931000
	atai	Net Income Attributable To Common Stockholders Basic And Diluted NetIncomeAttributableToCommonStockholdersBasicAndDiluted	-83249000
CY2021Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	151130212
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90709312
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	134334685
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90709312
CY2021Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.92
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.92
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	43002672
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23196877
CY2020Q3	atai	Related Party Reservation Rate Of Common Shares For Ipo RelatedPartyReservationRateOfCommonSharesForIpo	0.27

Files In Submission

Name	View Source	Status
0000950170-21-004541-index-headers.html	Edgar Link	pending
0000950170-21-004541-index.html	Edgar Link	pending
0000950170-21-004541.txt	Edgar Link	pending
0000950170-21-004541-xbrl.zip	Edgar Link	pending
atai-20210930.htm	Edgar Link	pending
atai-20210930.xsd	Edgar Link	pending
atai-20210930_cal.xml	Edgar Link	unprocessable
atai-20210930_def.xml	Edgar Link	unprocessable
atai-20210930_htm.xml	Edgar Link	completed
atai-20210930_lab.xml	Edgar Link	unprocessable
atai-20210930_pre.xml	Edgar Link	unprocessable
atai-ex31_1.htm	Edgar Link	pending
atai-ex31_2.htm	Edgar Link	pending
atai-ex32_1.htm	Edgar Link	pending
atai-ex32_2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img104097429_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATAI
ATAI Life Sciences NV Stock $atai

2021 Q4 Form 10-Q Financial Statement

#000095017021004541 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATAI ATAI Life Sciences NV Stock $atai

2021 Q4 Form 10-Q Financial Statement

#000095017021004541 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATAI
ATAI Life Sciences NV Stock $atai